Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
With data from 2 US claims databases (Optum, CVS Health) supplemented with Immunization Information System COVID-19 vaccine records, we evaluated overall and time-specific vaccine effectiveness (VE) of an initial primary series for 3 monovalent COVID-19 vaccines-BNT162b2, mRNA-1273, and JNJ-7836735-in adults (18-64 years). Vaccinated individuals were matched to unvaccinated comparators, and we estimated VE against any medically diagnosed COVID-19 and hospital/emergency department (ED)-diagnosed COVID-19. Additionally, we estimated VE by era of predominant variants, in subgroups, and compared across vaccine brands. The cohorts consisted of 341,097 (Optum) and 1,151,775 (CVS Health) matched pairs for BNT162b2; 201,604 (Optum) and 651,545 (CVS Health) for mRNA-1273; and 49,285 (Optum) and 149,813 (CVS Health) for JNJ-7836735. The study period began 11 December 2020 (date of first COVID-19 vaccine availability in the US) and ended 15 January 2022 in Optum and 31 March 2022 in CVS Health. Summary VE estimates from meta-analysis against hospital/ED-diagnosed COVID-19 were: BNT162b2, 77% (95% CI, 76%-78%); mRNA-1273, 84% (95% CI, 83%-85%), JNJ-7836735 66% (95% CI, 63%-68%). VE estimates were higher for hospital/ED-diagnosed COVID-19 than for medically diagnosed COVID-19, and VE estimates were highest in adults receiving mRNA-1273 for both outcomes. VE was sustained for approximately 7 months for medically diagnosed and up to 9 months for hospital/ED-diagnosed COVID-19. VE differed by brand and variant era. Ongoing real-world surveillance of COVID-19 vaccines using robust data sources and methodology is needed as new variants and recommendations for updated vaccines have evolved.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States
- Date Crossref
- 06/05/2025
- Éditeur
- Public Library of Science (PLoS)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
RTI Health Solutions pays non établi dans la noticeOrganisation à but non lucratif
-
Center for Biologics Evaluation and Research pays non établi dans la noticeStructure de recherche
-
New England College of Optometry pays non établi dans la noticeUniversité ou école supérieure
-
Acumen (United States) pays non établi dans la noticeEntreprise
-
RTI International pays non établi dans la noticeOrganisation à but non lucratif
-
Optum Epidemiology pays non établi dans la noticeInstitution
-
Acumen LLC pays non établi dans la noticeInstitution
-
Safety Surveillance & Collaboration pays non établi dans la noticeInstitution
-
OptumServe pays non établi dans la noticeInstitution
RTI Health Solutions, Center for Biologics Evaluation and Research et New England College of Optometry, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.